Patient P-02094

Synthetic patientMETA-24 · Day 171 · 35–44 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −18% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 71 SC-12 recommended — Supportive Compound SC-12
Day 72 Patient accepted — Started SC-12 in the companion
Day 77 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 78 No meaningful change — Supportive Compound SC-12
Day 80 GI-04 recommended — GI Support Protocol GI-04
Day 81 Patient declined — Not now
Day 87 ME-01 recommended — Monitoring Escalation ME-01
Day 88 Patient accepted — Started ME-01 in the companion
Day 91 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 77.

Primary contributors, last 14 days

Treatment adherence+10
Nutritional resilience+9
Toxicity-7
GI instability-5

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −18%
Supportive Compound SC-12Day 71
Result: no meaningful change
GI Support Protocol GI-04Day 80
Declined by patient
Monitoring Escalation ME-01Day 87
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
89% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

13 min

improving · +2.6 vs previous 14 d

Sleep duration

Wearable

5.6 h

stable · +0.0 vs previous 14 d

Energy level

Daily log

2.8/10

improving · +0.1 vs previous 14 d

Steps

Wearable

574

improving · +278 vs previous 14 d

GI burden

Companion

66.1/100

stable · +0.8 vs previous 14 d

Adherence

Companion

53 %

improving · +2.9 vs previous 14 d

Sleep quality

Wearable

13/100

stable · -0.4 vs previous 14 d

Glucose, CGM daily mean

CGM

150 mg/dL

stable · +2.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 29 from the failing basin, 71 from restoration.

Would help

GI-04 GI Support Protocol
77% improved among 65 similar · onset 8 d · confidence 97%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 81%
HY-01 Hydration Protocol
60% improved among 5 similar · onset 4 d · confidence 81%
More protein
GI -6.8 next day on high-intake days · n 25

Would not help

SC-12 Supportive Compound
already tried, no meaningful change
Keep fat low
GI +6.9 next day on high-intake days · n 25
Keep histamine low
GI +6.5 next day on high-intake days · n 22
Keep ultra-processed low
GI +4.5 next day on high-intake days · n 22

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.9detractor · 95%
Protein
-6.8supporter · 95%
Histamine load
+6.5detractor · 95%
Ultra-processed food
+4.5detractor · 95%
Simple carbohydrates
+3.1detractor · 59%
Insoluble fibre
-1.7no signal · 21%
Caffeine
+1.3no signal · 20%
Alcohol
+1.1no signal · 22%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 66 and rising
- WearableSleep 5.6 h, below personal baseline
Inflammatory signalling ↓40
- BloodInflammatory load index 68
- WearableHRV 26 ms, trending down
Autonomic recovery ↑40
- Wearable574 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 55

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.3 · butyrate capacity 40/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 6.0 h
Steps: 968
Resting HR: 69 bpm

Daily log: GI score 66, nutritional resilience 36, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02048	19%	S02	—	—	77
P-02115	22%	S14	GI-04	improved	75
P-02575	24%	S14	ME-01	improved	73
P-02553	19%	S13	—	—	71
P-02550	20%	S01	—	—	70
P-02192	19%	S05	—	—	69
P-02659	25%	S09	—	—	69
P-02083	18%	S13	—	—	69
P-02293	19%	S15	HY-01	no change	68
P-02591	34%	S13	—	—	68
P-02090	19%	S04	—	—	68
P-02265	32%	S07	GI-04	no change	67